Epi-Genetic Modulators of Fear Extinction in Alcohol Dependence
NCT02438969 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96
Last updated 2026-02-17
Summary
Background:
\- Researchers want to learn if people with alcohol dependence have more difficulty learning to feel calm, or learn to fear things more easily. They also want to study how early life stress (ELS) affects the ability to learn to feel calm.
Objective:
\- To see if people with alcohol dependence and/or ELS have a harder time learning to feel calm than people without these. Also, to see if DNA is changed by ELS and if this change affects fear conditioning and extinction.
Eligibility:
* Adults ages 21-65 with and without an alcohol use disorder (AUD) and with and without ELS.
* Healthy volunteers.
Design:
* Participants will be screened with:
* Medical history
* Physical exam
* Blood and urine tests
* Psychological tests
* Treatment for symptoms of alcohol withdrawal, if needed
* Healthy volunteers will have 1 overnight visit (2 days, 1 night). AUD participants will stay at the clinic for about 4 weeks.
* Participants will:
* Rate alcohol use/craving, depression, anxiety, and childhood trauma.
* Have psychophysiological measures: electrodes and mild electric shock.
* Have a functional magnetic resonance imaging (MRI) scan. Participants will lie on a table in a metal cylinder with a coil over their head. In the first scanning session, they will see pictures, do a simple task, and may get shocks. Participants will also do a second scanning session in which they will perform the aforementioned fear conditioning and extinction task, as well as a facial expression matching task, an affective word processing task, and a task measuring valuation of monetary rewards.
* Answer questions about their emotions (some participants).
* Have blood drawn from an arm vein or intravenous (IV) line.
* AUD participants will get a dexamethasone pill. The next day, they will get a hormone injected in and have blood drawn from an IV line.
* AUD participants will have 3 follow-up visits with questions and blood and lab tests.
Conditions
- Fear
- Stress
- Alcohol Dependence
Sponsors & Collaborators
-
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
lead NIH
Principal Investigators
-
Falk W Lohoff, M.D. · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eligibility
- Min Age
- 21 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-08-13
- Primary Completion
- 2022-12-30
- Completion
- 2022-12-31
Countries
- United States
Study Locations
More Related Trials
-
The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD
NCT00896038 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
NCT02884908 ·Status: COMPLETED ·Phase: PHASE3
-
A Gene by Medication Interaction to the Acute Effects of Alcohol
NCT01343628 ·Status: TERMINATED ·Phase: PHASE1
-
Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics
NCT00605904 ·Status: COMPLETED ·Phase: PHASE2
-
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
NCT05223829 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Understanding Psychological Distress and Therapeutic Environment in the Emergency Department
NCT06655467 ·Status: NOT_YET_RECRUITING
-
Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse
NCT02616094 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of High Dose Baclofen for Alcohol Dependence
NCT01980706 ·Status: COMPLETED ·Phase: PHASE2
-
Neural Substrates of Approach-Avoidance Conflict
NCT02119624 ·Status: COMPLETED
-
Oxytocin Treatment of Alcohol Dependence
NCT02251912 ·Status: COMPLETED ·Phase: PHASE2
-
Ethanol Response in Essential Tremor: Clinical and Neurophysiological Correlates
NCT01200966 ·Status: COMPLETED
-
The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD
NCT02469259 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Sex Differences in Risk for Alcohol Abuse
NCT04543942 ·Status: COMPLETED ·Phase: NA
-
INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers
NCT02989662 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Development of a Selective ALDH2 Inhibitor to Treat AUD
NCT04311294 ·Status: WITHDRAWN ·Phase: PHASE2
-
GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence
NCT00611767 ·Status: COMPLETED ·Phase: NA
-
A Response Modulation Hypothesis of Socioemotional Processing Associated With Alcohol Use Disorder
NCT03535129 ·Status: COMPLETED ·Phase: NA
-
Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk Behaviors
NCT04360018 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Alcohol Withdrawal in Hospital Patients
NCT00249366 ·Status: COMPLETED ·Phase: PHASE4
-
GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)
NCT00681655 ·Status: COMPLETED ·Phase: NA
-
Pregabalin as Treatment for Alcohol Use Disorder
NCT03256253 ·Status: COMPLETED ·Phase: PHASE2
-
Ketamine/Placebo Family History Positive Study
NCT00588952 ·Status: COMPLETED ·Phase: NA
-
Anxiety During Abstinence in AUD
NCT06793488 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Baclofen for the Treatment of Alcohol Drinkers
NCT01604330 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Stress, Hypothalamic-pituitary-adrenal (HPA) Dysfunction, and Relapse in Alcoholism
NCT00744588 ·Status: COMPLETED